Expanding the Use of an Immunotherapeutic to Colorectal Cancer
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
Progress Against Cancer
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
The FDA approved the first of a new class of immunotherapy known as CAR T-cell therapy for treating patients with acute lymphoblastic leukemia.
The FDA approved a molecularly targeted therapeutic for treating certain patients with HER2-positive breast cancer.
The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer. The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab (Keytruda) for the treatment of certain...
The FDA approved the first cancer treatment for use based on the tumor having certain biomarkers and not where in the body the tumor originated.
The FDA approved an immune checkpoint inhibitor – a type of immunotherapy – to treat certain patients with bladder cancer.
The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.
The FDA expanded the use of regorafenib to treat certain patients with the most common form of liver cancer diagnosed in the U.S. – hepatocellular carcinoma.
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now